Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe
ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of
blindness for the chronic and persistent inflammatory state in the eyes, which results in
continuous destroy in the structure of the eyes and gradually leads to irreversible damage on
visual function. However, it shows limiting efficacy of current treatment including
glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline
has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has
been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory
diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic
autoimmune uveitis with retinal degenerative changes.